-
ECONOMIC EVALUATION OF CONTINUOUSGLUCOSE MONITORING DEVICES VERSUS SMBG FOR TYPE 1 DIABETIC CHILDREN IN EGYPT FROM A SOCIETAL PERSPECTIVE
Aug 11, 2026, 17:15 PM -
COST-EFFECTIVENESS ANALYSIS OF VILLAGE IN A DISH AS A PHARMACOGENOMIC TEST TO PREDICT TREATMENT OUTCOMES OF RILUZOLE VERSUS EDARAVONE FOR AMYOTROPHIC LATERAL SCLEROSIS PATIENTS
Aug 11, 2026, 17:15 PM -
GLP-1 RECEPTOR AGONISTS FOR ALCOHOL USE DISORDER: INDICATION POSITIONING AND HTA/JCA IMPLICATIONS
Aug 11, 2026, 17:15 PM -
PROSPECTIVE AI-ENABLED PICO PREDICTION FOR EU JOINT CLINICAL ASSESSMENT: BLINDED VALIDATION USING THE FIRST PUBLISHED JCA REPORT ON TOVORAFENIB
Aug 11, 2026, 17:15 PM -
COMPARISON OF NAIVE VERSUS DELAYED-ENTRY ADJUSTMENT METHODS IN REAL-WORLD SURVIVAL ANALYSIS OF FIRST-LINE METASTATIC NSCLC WITH PD-L1 TPS =50%
Aug 11, 2026, 17:15 PM -
FROM MECHANISM TO VALUE: A STRATEGIC FRAMEWORK FOR EARLY ECONOMIC MODELING OF DISEASE-MODIFYING THERAPIES ACROSS THE DEVELOPMENT LIFECYCLE
Aug 11, 2026, 17:15 PM -
EVALUATING FULLY AUTOMATED FULL-TEXT SCREENING FOR HTA SYSTEMATIC REVIEWS
Aug 11, 2026, 17:15 PM -
EVALUATION OF USE OF OVERALL SURVIVAL AS CO-PRIMARY OR SECONDARY ENDPOINT IN CROSSOVER TRIALS: A SYSTEMATIC LITERATURE REVIEW OF HEALTH TECHNOLOGY ASSESSMENT (HTA) SUBMISSIONS OF TREATMENTS FOR SELECT TUMORS IN ONCOLOGY
Aug 11, 2026, 17:15 PM -
WHEN EVIDENCE FAILS TO CHANGE DECISIONS: THE MISSING LINK BETWEEN MEASUREMENT AND VALUE IN HEALTHCARE
Aug 11, 2026, 17:15 PM -
HEALTH STATE UTILITIES ASSOCIATED WITH OTOFERLIN-RELATED HEARING LOSS
Aug 11, 2026, 17:15 PM -
WHEN ONE MAIC BECOMES ONE TOO MANY: MULTIPLICITY AND EVIDENCE INTERPRETATION IN THE EU JOINT CLINICAL ASSESSMENT CONTEXT
Aug 11, 2026, 17:15 PM -
VALUE OF TELEMONITORING FOR POSITIVE AIRWAY PRESSURE THERAPY MANAGEMENT IN OBSTRUCTIVE SLEEP APNEA: A SYSTEMATIC LITERATURE REVIEW
Aug 11, 2026, 17:15 PM -
COST-CONSEQUENCE ANALYSIS OF HIGH-EFFICACY DISEASE-MODIFYING THERAPIES IN RELAPSING-REMITTING MULTIPLE SCLEROSIS PATIENTS WITH COMORBIDITY BURDEN IN SPAIN
Aug 11, 2026, 17:15 PM -
MODELING THE CLINICAL AND ECONOMIC IMPACT OF CLESROVIMAB AGAINST RESPIRATORY SYNCYTIAL VIRUS AMONG INFANTS IN ITALY
Aug 11, 2026, 17:15 PM -
REPORTING FIDELITY OF PRIMARY ENDPOINTS IN FDA-APPROVED NSCLC THERAPIES: AN EXTENSION OF THE COMPARE METHOD
Aug 11, 2026, 17:15 PM -
PRISMA-PERFECT? CHECKING ISPOR ABSTRACTS' ALIGNMENT WITH PRISMA-A 2020
Aug 11, 2026, 17:15 PM -
SUCCESSFUL IMPLEMENTATION OF AN AUTOMATED MEDICATION DISPENSING AND TELECOMMUNICATION SERVICE REDUCES HOMECARE CONTACTS AND COSTS AMONG HOMECARE CLIENTS
Aug 11, 2026, 17:15 PM -
ECONOMIC BURDEN OF TYPE 2 DIABETES MELLITUS IN INDIA: AN ANALYSIS OF HEALTHCARE RESOURCE UTILISATION, OUT-OF-POCKET EXPENDITURE, AND FUNCTIONAL OUTCOMES USING NATIONALLY REPRESENTATIVE SURVEY DATA
Aug 11, 2026, 17:15 PM -
HEALTHCARE RESOURCE UTILIZATION (HCRU) AND ASSOCIATED ECONOMIC BURDEN OF METASTATIC UROTHELIAL CANCER (MUC) IN FRANCE USING THE SYSTEME NATIONAL DES DONNEES DE SANTE (SNDS) DATABASE: A RETROSPECTIVE COHORT STUDY
Aug 11, 2026, 17:15 PM -
FRAGMENTED CARE INTERFACES: EVALUATING INTERSECTORAL COMMUNICATION BARRIERS AND DIGITAL HEALTH INTEGRATION IN RURAL CARE PATHWAYS
Aug 11, 2026, 17:15 PM
